BioSpace News Archive

Successful models selected by Open Source Malaria consortium will be progressed through to design novel compounds for synthesis and testing

Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota, announced the results of DAV132CL-1005, a Phase 1 clinical study which investigated the potential effect of DAV132 on the bioavailability of warfarin or clonazepam, two widely used drugs with narrow therapeutic index.

New certification demonstrates commitment to the highest standards of data protection across the company’s operations, systems, and products

GenomSys, a software company which develops technology for efficient processing and sharing of DNA data, announces a collaboration with SysMeta IT, a digital services company catering to medical clinics and labs in Switzerland and editor of Tangerine Medical and Tangerine Diagnostics software packages.

Several trends have emerged in synthetic biology since the field developed nearly 20 years ago. In that time, some technologies have crystallized and developed into key trends that crop up time again within synthetic biology conversations.

Two weeks after the pharmaceutical industry predicted dire consequences for innovation if the prescription price reduction plan proposed by House Speaker Nancy Pelosi passes, the White House is now echoing those concerns but suggesting even worse outcomes than industry analysts predict.

Plasmid DNA Manufacturer VGXI, Inc. Selects BE&K Building Group as its Design-Build Partner for the Initial Phase of its New and Expanded Manufacturing Facility

Bpifrance and Pfizer Ventures co-led international investor syndicate

Aeroflow to provide high-quality medical equipment through insurance to MTI America policyholders.

Phoenix Solutions AS, a clinical-stage biotech company, announced the appointment of Dr. Jean-Michel Cosséry to its Board of Directors.